Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase III trial after a 19-month clinical hold by the ...

The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta Pharma’s C-CAR168.

In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity.

PL logistics need to invest in new technology and upskilling programs to scale their cell and gene therapy services.

GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support its lead IgG4-targeted protein ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging ...

Cell and gene therapy (C&GT) is set to revolutionise treatment of complex diseases, offering new possibilities for patients.

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

The 12th Outsourcing in Clinical Trials UK & Ireland conference will focus on the region’s future as a clinical trials hub.

GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

With the 78th World Health Assembly ending today, all eyes have been on this year’s World Health Organization (WHO) member’s ...